Comparing Pegfilgrastim and Filgrastim for Neutrophil Recovery in AML
Author Information
Author(s): Sierra Jorge, Szer Jeffrey, Kassis Jeannine, Herrmann Richard, Lazzarino Mario, Thomas Xavier, Noga Stephen J, Baker Nigel, Dansey Roger, Bosi Alberto
Primary Institution: Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hypothesis
Is a single dose of pegfilgrastim as effective as daily filgrastim for neutrophil recovery in patients with acute myeloid leukemia?
Conclusion
There is no clinically meaningful difference between a single dose of pegfilgrastim and multiple daily doses of filgrastim for shortening the duration of severe neutropenia following chemotherapy in AML patients.
Supporting Evidence
- Both treatment groups had similar median times to recovery from severe neutropenia.
- Pegfilgrastim was well tolerated with an adverse event profile similar to filgrastim.
- The study included 84 patients from 27 sites across Australia, Europe, and North America.
Takeaway
This study looked at two medicines that help patients recover from low white blood cell counts after chemotherapy. It found that one dose of pegfilgrastim works just as well as taking filgrastim every day.
Methodology
Patients received standard induction chemotherapy followed by either pegfilgrastim or filgrastim to assist neutrophil recovery.
Potential Biases
Potential bias due to early termination of the study and patient withdrawals.
Limitations
The study was prematurely closed, which may have affected the power and generalizability of the results.
Participant Demographics
Patients aged 18 and older with de novo AML, with a median age of 51 years for pegfilgrastim and 54 years for filgrastim.
Statistical Information
P-Value
0.5
Confidence Interval
95% CI: -1.9 to 1.9
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website